This document provides an overview of a company's financial performance from 2010-2011. It discusses the company's consolidated turnover which increased 7% from 2010 to 2011. It also breaks down the financial results by section, showing growth in most regions except emerging markets and corporate costs. Finally, it analyzes results by the top 5 brands, which saw a 13% increase in sales and now make up over 54% of total turnover.
2. Contents
• About the company
• Financial story 2010-2011
Consolidated turnover
Turnover per section
Turnover per brand
For the investors/potential investors
• Conclusion
Aida De Jonge - 2BAF02 2
3. The company
• OTC – company prescription free products
• Pharmacists
• More than 2000 brands: Davitamon, XLS medical,
Dermalex, Galenco…
• Active in more than 35 countries
• Belgian company International OTC – company
Aida De Jonge - 2BAF02 3
4. The financial story
Consolidated turnover 2010/2011
(Mill. Euro) 2011 2010 Difference in %
Consolidated turnover 454,4 423,5 7%
Gross margin 242,2 225,9 7%
Operating costs -178,6 -165,8 7%
EBITDA 64,7 60,1 8%
Net recurrent result 33,8 33,7 0%
Aida De Jonge - 2BAF02 4
5. The financial story
Results per section
(Mill. Euro) Turnover EBITDA(= operational cash flow)
2010 2011 Evolution 2011 Margin (% of turnover) 2010 Evolution
Western Europe 175,8 184,8 5,20% 36,9 20% 35,4 4%
Belgium 124,6 134,3 7,80% 21,4 15,90% 18,2 18%
Emerging markets 46,4 48,5 4,50% 5,4 11,10% 4,3 26%
France 76,7 86,9 13,20% 11,6 13,30% 9,1 27%
Corporate -10,6 -6,9 54%
Total 454,5 7,30% 64,7 14,20% 67 8%
Aida De Jonge - 2BAF02 5
6. The financial story
Results per brand
2011 2010 Evolution
Derma 102988 97978 5%
Classics 53684 45062 19%
Parasites 40795 39609 3%
Cough & Cold ( & Allergy) 33350 18871 77%
Multi-Locals 15519 16307 -5%
Subtotal of the 5 brands 246336 217827 13%
% of the total turnover 54,20% 51,40%
Aida De Jonge - 2BAF02 6
